FindTrial
Sign In

IDO1 Inhibitor BMS-986205

BIOLOGICAL2 trials

Sponsors

Edward Kim, Thomas Jefferson University

Conditions

LarynxLipMetastatic Hepatocellular CarcinomaOral Cavity Squamous Cell CarcinomaPharynxSquamous Cell CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8

Phase 1

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
TerminatedNCT03695250
Edward KimMetastatic Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8 +5
Start: 2018-10-16End: 2021-03-12Updated: 2026-07-29

Phase 2

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Active, not recruitingNCT03854032
Thomas Jefferson UniversityLarynx, Lip, Oral Cavity Squamous Cell Carcinoma +2
Start: 2019-04-09End: 2025-12-31Updated: 2025-06-06

Related Papers

Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.
2025-12-011 citations
Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research2024-11-255 citations
Predictive capacity of immune‐related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma
Cancer Medicine2024-06-016 citations
555 Challenges in predicting ICI response in HPV+ HNSCC: insights into the tumor microenvironment
Regular and Young Investigator Award Abstracts2023-10-31
222-K Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)
2023-10-31
Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.
Journal of Clinical Oncology2022-06-018 citations
Phase I/II trial of BMS-986205 and nivolumab as first line therapy in hepatocellular carcinoma.
Journal of Clinical Oncology2022-06-012 citations
Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable squamous cell carcinoma of the head and neck (SCCHN).
Journal of Clinical Oncology2020-05-206 citations
Phase I/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma.
Journal of Clinical Oncology2019-03-104 citations